Ascendant Health Sciences

Ascendant Health Sciences is a specialty pharmaceutical company focused on the development and commercialization of innovative topical and transdermal drug delivery systems. A division of Ascendant Health, the company leverages proprietary formulations to improve the efficacy and safety of existing medications, particularly in the field of pain management. Its lead candidate, AHS-001, is a topical combination of ketamine, gabapentin, and lidocaine designed to treat neuropathic pain with reduced systemic side effects. The company's research and development efforts are centered on addressing unmet needs in chronic pain through non-opioid, localized therapies. Ascendant Health Sciences aims to provide clinicians and patients with effective alternatives to oral analgesics, minimizing the risk of systemic toxicity and addiction.